Yahoo
    NasdaqCM - Nasdaq Real Time Price USD

    vTv Therapeutics Inc. (VTVT)

    25.72 0.00 (0.00%)
    At close: October 28 at 4:00:00 PM EDT
    Trade VTVT on Coinbase
    Chart Range Bar
    Advanced Chart
    AlphaSpace Chart
    Loading chart for VTVT
    • Previous Close 25.72
    • Open 25.55
    • Bid 25.37 x 100
    • Ask 26.65 x 900
    • Day's Range 25.00 - 25.96
    • 52 Week Range 19.80 - 44.00
    • Volume 17,881
    • Avg. Volume 52,287
    • Market Cap (intraday) 101.695M
    • Beta (5Y Monthly) 0.21
    • PE Ratio (TTM) --
    • EPS (TTM) -0.72
    • Earnings Date (est.) Nov 13, 2026
    • Forward Dividend & Yield -- (0.00%)
    • 1y Target Est 56.00
    • Zacks Rating Neutral

    vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company is also investing a range of molecules across various indications for chronic diseases. It has a license agreement Newsoara Biopharma Co., Ltd. to develop and commercialize phosphodiesterase type 4 inhibitors program. vTv Therapeutics Inc. was incorporated in 2015 and is headquartered in High Point, North Carolina.

    vtvtherapeutics.com

    26

    Full Time Employees

    December 31

    Fiscal Year Ends

    Healthcare

    Sector

    Biotechnology

    Industry

    More about vTv Therapeutics Inc.

    Recent News

    View More
    View More

    Performance Overview

    Trailing total returns as of 10/28/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

    YTD Return

    VTVT
    35.68%
    S&P 500 (^GSPC)
    13.13%

    1-Year Return

    VTVT
    23.12%
    S&P 500 (^GSPC)
    12.38%

    3-Year Return

    VTVT
    48.50%
    S&P 500 (^GSPC)
    88.08%

    5-Year Return

    VTVT
    54.40%
    S&P 500 (^GSPC)
    68.48%

    Earnings Trends

    View More

    Earnings Per Share

    GAAP
    Normalized
    GAAP
    Normalized

    Revenue vs. Earnings

    Annual
    Quarterly
    Annual
    Quarterly
    Q2 FY26
    Revenue --
    Earnings -13.05M
    Profit Margin 0.00%

    Q3

    FY25

    Q4

    FY25

    Q1

    FY26

    Q2

    FY26

    -10M
    0
    10M
    20M
    30M
    0.0%
    20.0%
    40.0%
    60.0%
    View More

    Analyst Insights

    View More

    Analyst Price Targets

    42.00
    56.00 Average
    25.72 Current
    67.00 High

    Analyst Recommendations

    • Strong Buy
    • Buy
    • Hold
    • Underperform
    • Sell

    Latest Rating

    Date 10/14/2026
    Analyst BTIG
    Rating Action Reiterates
    Rating Buy
    Price Action Maintains
    Price Target 57 -> 57
    View More

    Statistics

    View More

    Valuation Measures

    Annual

    • Market Cap

    • Enterprise Value

    • Trailing P/E

    • Forward P/E

    • PEG Ratio (current)

    • Price/Sales (ttm)

    • Price/Book (mrq)

    • Enterprise Value/Revenue

    • Enterprise Value/EBITDA

    Financial Highlights

    Profitability and Income Statement

    • Profit Margin

      -12.91%

    • Return on Assets (ttm)

      -10.14%

    • Return on Equity (ttm)

      -15.80%

    • Revenue (ttm)

      36.84M

    • Net Income Avi to Common (ttm)

      -4.76M

    • Diluted EPS (ttm)

      -0.72

    Balance Sheet and Cash Flow

    • Total Cash (mrq)

      86.64M

    • Total Debt/Equity (mrq)

      --

    • Levered Free Cash Flow (ttm)

      674.38k

    View More

    Company Insights

    Research Reports

    View More
    View More

    People Also Watch

    XBIO
    OGEN
    TENX
    TRVN
    DARE
    Mobilize your Website
    View Site in Mobile | Classic
    Share by: